Anika Therapeutics (ANIK) vs Emergent BioSolutions (EBS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Anika Therapeutics (ANIK) has outperformed Emergent BioSolutions (EBS) over the past year, gaining 114.9% versus a loss of 28.7%. Over five years, ANIK leads with a -53.1% price change compared with -86.1% for EBS. Emergent BioSolutions is the larger company by market cap ($362.5 million vs $261.4 million), about 1.4 times the size.
On valuation, Emergent BioSolutions trades at a lower forward P/E (6.8x vs 20.6x for Anika Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIK | EBS |
|---|---|---|
| Share price | $19.53 | $7.07 |
| Market cap | $261.37M | $362.50M |
| 1-day change | +2.14% | +1.73% |
| YTD return | +103.23% | -42.80% |
| 1-year return | +114.85% | -28.73% |
| 5-year return | -53.12% | -86.05% |
| Forward P/E | 20.56 | 6.76 |
| EPS (TTM) | $-0.23 | $-3.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.88 | $14.06 |
| 52-week low | $8.67 | $4.36 |
| Distance from 52-week high | -14.64% | -49.72% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +17.77% | +55.59% |
| Average volume | 98.57K | 1.16M |
| Shares outstanding | 13.38M | 51.27M |
| Employees | 235 | 900 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANIK has outperformed EBS by 143.6 percentage points over the past year.
About Anika Therapeutics
ANIK stock →Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation.
Health Care · Medical/Dental Instruments · 235 employees
About Emergent BioSolutions
EBS stock →Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 900 employees
ANIK vs EBS FAQ
Which is bigger, Anika Therapeutics or Emergent BioSolutions?
Emergent BioSolutions (EBS) is larger, with a market capitalization of $362.50M compared with $261.37M for Anika Therapeutics (ANIK).
Which stock has performed better over the past year, ANIK or EBS?
ANIK returned +114.85% over the past 12 months, compared with -28.73% for EBS (price return, excluding dividends). Past performance does not predict future results.
Are Anika Therapeutics and Emergent BioSolutions in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Anika Therapeutics and Biotechnology: Pharmaceutical Preparations for Emergent BioSolutions.